23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › RIGEL PHARMACEUTICALS INC. › 2023-2024

RIGEL PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed May 29, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Reported items
  • 128Asset managers, any item
  • 1,012Fund votes
  • May 24, 2024Meeting date

Results at a glance

Meeting of May 24, 2024: 4 items on RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed May 29, 2024: 2 elected · 2 approved.

Dissent

Significant dissent: 2 directors (23.7%, 23.0% against).

Notable dissent: 1 say-on-pay vote (74.0% support); 1 other board item (47.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore RIGEL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by RIGEL PHARMACEUTICALS INC.

These tallies are RIGEL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

RIGEL PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 24, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Brian L. Kotzin 78,451,723--1,529,351 24,372,50626,314,869 76%Elected—
Elect Director: Gregg A. Lapointe 79,150,066--1,525,575 23,677,93926,314,869 77%Elected—
Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan. 53,147,92448,240,1562,965,500 --26,314,869 52.4%Approved—
Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. 74,738,20626,220,0783,395,296 --26,314,869 74%Approved—

Source: RIGEL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 29, 2024 — read the filing on EDGAR.

How asset managers voted at the RIGEL PHARMACEUTICALS INC. 2023-2024 meeting

128 asset managers disclosed a vote on at least one RIGEL PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RIGEL PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Brian L. Kotzin

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 78,451,723WITHHELD: 24,372,506
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: Election of Directors: Brian L. Kotzin

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Brian L. Kotzin”): 78,451,723 for, 24,372,506 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the two nominees for director, to serve until the Company's 2027 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 29,062,828 for, 341,735 against, 88,669 abstained.

FOR
FOR: 29,062,828AGAINST: 341,735ABSTAIN: 88,669
Largest asset managers voting on “Election of Directors: Brian L. Kotzin” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,795,4170 00For
TIAA2,854,8410 00For
Delaware/Macquarie1,600,0000 00For
Voya1,305,1290 00For
Charles Schwab743,6150 00For
Equitable295,130314,730 00Mixed
BRIDGEWAY FUNDS INC521,2000 00For
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial147,3630 00For
AuguStar00 88,6690Abstain
Northern Trust75,6960 00For
Nationwide74,4670 00For
T. Rowe Price74,3320 00For
John Hancock67,4210 00For
Legg Mason66,5630 00For
Goldman Sachs60,6100 00For
Pacific Life57,8100 00For
Brighthouse56,7660 00For
Russell Investments51,6540 00For
AIG/SunAmerica45,4370 00For
Principal Exchange-Traded Funds39,6880 00For
Bridge Builder Trust35,3400 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Gregg A. Lapointe

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 79,150,066WITHHELD: 23,677,939
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: Election of Directors: Gregg A. Lapointe

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gregg A. Lapointe”): 79,150,066 for, 23,677,939 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the two nominees for director, to serve until the Company's 2027 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 29,075,023 for, 329,540 against, 88,669 abstained.

FOR
FOR: 29,075,023AGAINST: 329,540ABSTAIN: 88,669
Largest asset managers voting on “Election of Directors: Gregg A. Lapointe” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,795,4170 00For
TIAA2,854,8410 00For
Delaware/Macquarie1,600,0000 00For
Voya1,305,1290 00For
Charles Schwab743,6150 00For
Equitable295,130314,730 00Mixed
BRIDGEWAY FUNDS INC521,2000 00For
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial147,3630 00For
AuguStar00 88,6690Abstain
Northern Trust75,6960 00For
Nationwide74,4670 00For
T. Rowe Price74,3320 00For
John Hancock67,4210 00For
Legg Mason66,5630 00For
Goldman Sachs60,6100 00For
Pacific Life57,8100 00For
Brighthouse56,7660 00For
Russell Investments51,6540 00For
AIG/SunAmerica45,4370 00For
Principal Exchange-Traded Funds39,6880 00For
Bridge Builder Trust35,3400 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

To approve an amendment to the company's amended and restated certificate of incorporation to effect a reverse stock…

No official matchCAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 45 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF COMMON STOCK (WITHOUT REDUCING THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK), IF AND WHEN DETERMINED BY THE COMPANY'S BOARD OF DIRECTORS.

The 45 asset managers below reported 29,404,563 for, 88,669 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,404,563ABSTAIN: 88,669
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,795,4170 00For
TIAA2,854,8410 00For
Delaware/Macquarie1,600,0000 00For
Voya1,305,1290 00For
Charles Schwab743,6150 00For
Equitable609,8600 00For
BRIDGEWAY FUNDS INC521,2000 00For
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial147,3630 00For
AuguStar00 88,6690Abstain
Northern Trust75,6960 00For
Nationwide74,4670 00For
T. Rowe Price74,3320 00For
John Hancock67,4210 00For
Legg Mason66,5630 00For
Goldman Sachs60,6100 00For
Pacific Life57,8100 00For
Brighthouse56,7660 00For
Russell Investments51,6540 00For
AIG/SunAmerica45,4370 00For
Principal Exchange-Traded Funds39,6880 00For
Bridge Builder Trust35,3400 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

To approve the adjournment of the annual meeting to a later date or dates, if necessary, to permit further solicitation…

No official matchCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

99.1% of fund votes cast · no official result

FOR
Details: description as filed, votes by 45 asset managers

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOLICITATION AND VOTE OF PROXIES IN THE EVENT THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT.

The 45 asset managers below reported 29,133,784 for, 270,779 against, 88,669 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,133,784AGAINST: 270,779ABSTAIN: 88,669
Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOL” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,795,4170 00For
TIAA2,854,8410 00For
Delaware/Macquarie1,600,0000 00For
Voya1,305,1290 00For
Charles Schwab743,6150 00For
Equitable609,8600 00For
BRIDGEWAY FUNDS INC521,2000 00For
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial0147,363 00Against
AuguStar00 88,6690Abstain
Northern Trust75,6960 00For
Nationwide74,4670 00For
T. Rowe Price074,332 00Against
John Hancock67,4210 00For
Legg Mason66,5630 00For
Goldman Sachs60,6100 00For
Pacific Life57,8100 00For
Brighthouse56,7660 00For
Russell Investments51,6540 00For
AIG/SunAmerica45,4370 00For
Principal Exchange-Traded Funds39,6880 00For
Bridge Builder Trust35,3400 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.

Official resultCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

52.4% Approved · of votes cast

FOR 52.4%AGAINST
FOR: 53,147,924AGAINST: 48,240,156
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 6,500,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”): 53,147,924 for, 48,240,156 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”
Support: 52.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 24,524,201 for, 4,880,362 against, 88,669 abstained.

FORAGAINST
FOR: 24,524,201AGAINST: 4,880,362ABSTAIN: 88,669
Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an add” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,605,770189,647 00For
TIAA2,854,8410 00For
Delaware/Macquarie01,600,000 00Against
Voya01,305,129 00Against
Charles Schwab743,6150 00For
Equitable295,130314,730 00Mixed
BRIDGEWAY FUNDS INC0521,200 00Against
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial0147,363 00Against
AuguStar00 88,6690Abstain
Northern Trust075,696 00Against
Nationwide074,467 00Against
T. Rowe Price074,332 00Against
John Hancock067,421 00Against
Legg Mason066,563 00Against
Goldman Sachs060,610 00Against
Pacific Life57,8100 00For
Brighthouse056,766 00Against
Russell Investments51,6540 00For
AIG/SunAmerica045,437 00Against
Principal Exchange-Traded Funds039,688 00Against
Bridge Builder Trust35,3400 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

74% Approved · of votes cast

FOR 74%AGAINST
FOR: 74,738,206AGAINST: 26,220,078
Details: description as filed, official tally, votes by 128 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 74,738,206 for, 26,220,078 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 45 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,795,4170 00For
TIAA2,854,8410 00For
Delaware/Macquarie1,600,0000 00For
Voya1,305,1290 00For
Charles Schwab743,6150 00For
Equitable609,8600 00For
BRIDGEWAY FUNDS INC521,2000 00For
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial147,3630 00For
AuguStar00 88,6690Abstain
Northern Trust75,6960 00For
Nationwide74,4670 00For
T. Rowe Price74,3320 00For
John Hancock67,4210 00For
Legg Mason66,5630 00For
Goldman Sachs60,6100 00For
Pacific Life57,8100 00For
Brighthouse56,7660 00For
Russell Investments51,6540 00For
AIG/SunAmerica45,4370 00For
Principal Exchange-Traded Funds39,6880 00For
Bridge Builder Trust35,3400 00For

Fund voting reports, all 45 managers: 29,404,563 for, 88,669 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 98 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARMISTICE CAPITAL, LLC014,014,448 00Against
Soleus Capital Management, L.P.9,241,9860 00For
BlackRock6,641,1310 00For
GEODE CAPITAL MANAGEMENT, LLC3,792,4990 00For
State Street3,202,9690 00For
Nuveen2,864,1500 00For
ACADIAN ASSET MANAGEMENT LLC2,290,3270 00For
JACOBS LEVY EQUITY MANAGEMENT, INC2,118,2410 00For
Ensign Peak Advisors, Inc2,034,2040 00For
Voya1,804,9190 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST1,600,0000 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND1,359,2000 00For
Northern Trust1,276,346160 00For
Renaissance1,093,8000 00For
Stonepine Capital Management, LLC1,040,2410 00For
Charles Schwab743,6150 00For
MELLON INVESTMENTS Corp738,3050 00For
Two Sigma724,9750 00For
Wellington673,3250 00For
UBS672,75045 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC547,4000 00For
SEI477,9400 00For
MARSHALL WACE, LLP0438,562 00Against
Connor, Clark & Lunn Investment Management Ltd.415,4640 00For
AllianceBernstein314,7300 00For

Institutional-manager reports, all 98 managers: 48,740,842 for, 14,796,569 against. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the company for…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 45 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

The 45 asset managers below reported 29,404,563 for, 88,669 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,404,563ABSTAIN: 88,669
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPA” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,061,7180 00For
BlackRock6,943,6270 00For
Fidelity3,795,4170 00For
TIAA2,854,8410 00For
Delaware/Macquarie1,600,0000 00For
Voya1,305,1290 00For
Charles Schwab743,6150 00For
Equitable609,8600 00For
BRIDGEWAY FUNDS INC521,2000 00For
SEI475,4770 00For
QUANTITATIVE MASTER SERIES LLC305,2970 00For
Lincoln Financial147,3630 00For
AuguStar00 88,6690Abstain
Northern Trust75,6960 00For
Nationwide74,4670 00For
T. Rowe Price74,3320 00For
John Hancock67,4210 00For
Legg Mason66,5630 00For
Goldman Sachs60,6100 00For
Pacific Life57,8100 00For
Brighthouse56,7660 00For
Russell Investments51,6540 00For
AIG/SunAmerica45,4370 00For
Principal Exchange-Traded Funds39,6880 00For
Bridge Builder Trust35,3400 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Largest RIGEL PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 175,406,146 shares outstanding at the time of that meeting.

Fund voting reports: top RIGEL PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 5.17%
2BlackRock 3.96%
3Fidelity 2.16%
4TIAA 1.63%
5Delaware/Macquarie 0.91%
6Voya 0.74%
7Charles Schwab 0.42%
8Equitable 0.35%
9BRIDGEWAY FUNDS INC 0.30%
10SEI 0.27%
Institutional-manager reports: top RIGEL PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1ARMISTICE CAPITAL, LLC 7.99%
2Soleus Capital Management, L.P. 5.27%
3BlackRock 3.79%
4GEODE CAPITAL MANAGEMENT, LLC 2.16%
5State Street 1.83%
6Nuveen 1.63%
7ACADIAN ASSET MANAGEMENT LLC 1.31%
8JACOBS LEVY EQUITY MANAGEMENT, INC 1.21%
9Ensign Peak Advisors, Inc 1.16%
10Voya 1.03%

Reported RIGEL PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

RIGEL PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
The Vanguard Group8,953,217 5.10%Schedule 13G, filed February 13, 2024
Geode Capital3,792,499 2.16%Form 13F, quarter ended March 31, 2024
State Street3,734,799 2.13%Form 13F, quarter ended March 31, 2024
Nuveen3,223,350 1.84%Form 13F, quarter ended March 31, 2024
Renaissance Technologies2,020,191 1.15%Form 13F, quarter ended March 31, 2024
Millennium Management1,872,988 1.07%Form 13F, quarter ended March 31, 2024
Northern Trust1,447,748 0.83%Form 13F, quarter ended March 31, 2024
Wellington Management834,158 0.48%Form 13F, quarter ended March 31, 2024
Charles Schwab743,615 0.42%Form 13F, quarter ended March 31, 2024
BNY Mellon524,016 0.30%Form 13F, quarter ended March 31, 2024

Percentages above are of 175,406,146 shares outstanding, as reported by RIGEL PHARMACEUTICALS INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At RIGEL PHARMACEUTICALS INC.'s shareholder meeting held May 24, 2024, in the 2023-2024 proxy season, 128 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,012 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — RIGEL PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 74% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RIGEL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RIGEL PHARMACEUTICALS INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

RIGEL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “RIGEL PHARMACEUTICALS (RIGL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rigel-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.